The FDA has been sending out warning letters to companies that have been illegally selling unapproved CBD products, claiming that they can diagnose, cure, mitigate, treat, or prevent various diseases. In some cases, the FDA has also found that CBD has been added to food products. The only CBD product that the FDA has approved is a prescription drug for the treatment of rare and serious forms of epilepsy. In a recent study conducted by the FDA, it was found that only 45% of the products tested contained CBD within 20% of the indicated amount.
Out of the 102 products that included a specific amount of CBD, less than half (45%) contained CBD within 20% of the indicated amount. Additionally, out of the 41 cosmetics containing CBD, 12 products also contained THC, although this substance was not specified on their labels. It is important to note that the FDA has not approved any other cannabis product, derived from cannabis or cannabidiol (CBD) currently available on the market. Over-the-counter drugs must be approved by the FDA or meet marketing requirements without an application for a new drug approved under federal law, including drugs containing CBD, regardless of whether CBD appears on the label as an active ingredient or as an inactive ingredient.
The FDA has also expressed concern about CBD products marketed to food-producing animals and possible safety issues related to food products for human use. New tests conducted by the FDA found that almost half of the randomly selected cannabidiol (CBD) products also tested positive for THC, the main active compound in marijuana, calling into question the accuracy of labeling CBD products. In addition to violations related to FDA-regulated products containing delta-8 THC, several of the warning letters describe other violations of the FD%26C Act, such as the marketing of CBD products that claim to treat human and animal conditions, the promotion of CBD products as dietary supplements, and the addition of CBD to food for humans and animals.
